Ratings Naturhouse Health, S.A.

Equities

NTH

ES0105043006

Market Closed - BME 11:35:23 2024-05-28 am EDT 5-day change 1st Jan Change
1.67 EUR +2.77% Intraday chart for Naturhouse Health, S.A. +1.21% +3.09%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 9.56 for the current year.
  • The company has a low valuation given the cash flows generated by its activity.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • Most analysts recommend that the stock should be sold or reduced.

Ratings chart - Surperformance

Sector: Other Specialty Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
+3.09% 106M -
+30.82% 30.4B
A-
+7.44% 5.89B
B-
-17.46% 4.17B
C
+6.85% 4B
C+
+4.23% 1.91B -
B-
-8.36% 1.69B
C+
-15.50% 1.23B -
C
-13.44% 1.16B
B-
-21.13% 944M
D+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NTH Stock
  4. Ratings Naturhouse Health, S.A.